Our history

Theratechnologies was founded in 1993. Scientists at Theratechnologies discovered EGRIFTA® (tesamorelin for injection) in 1995. For the next fifteen years, Theratechnologies pursued the development of this innovative treatment for lipodystrophy in people living with HIV. In 2010, Theratechnologies received a marketing authorization for EGRIFTA® from the Food and Drug Administration in the United States.

To be a biopharmaceutical company which successfully brings to market exceptional innovations.

World EN Placeholder
World EN
World Point EN Placeholder
World Point EN
Our offices
  • Our offices
    Montreal

    Theratechnologies employs 40 people at its head office located at 2015 Peel Street, 11th floor, Montreal, Quebec H3A 1T8.

    Dublin

    Theratechnologies European head office is located in Dublin, Ireland. Around ten people are working at this office located at 2 rue Hume Street, 4th floor, Dublin 2, D02 DV24.

  • Covered Territories
    Canada
    United States
    Mexico
    Denmark
    Estonia
    Finland
    United Kingdom
    Ireland
    Lithuania
    Latvia
    Sweden
    Austria
    Belgium
    Germany
    France
    Liechtenstein
    Luxembourg
    Monaco
    Netherlands
    Bulgaria
    Czechia
    Hungary
    Poland
    Romania
    Slovakia
    Albania
    Spain
    Gibraltar
    Greece
    Croatia
    Italy
    Malta
    Portugal
    Slovenia
    Cyprus
    Greece

Theratechnologies around the world

Theratechnologies operates in Canada, the United States and Europe.

Our mission

We develop and commercialize cutting-edge treatments addressing unmet medical needs which give new options for health care practitioners and hope to patients.

Our values

Agility

The Company operates in a highly competitive and regulated field. We must constantly be creative and resourceful in finding innovative solutions that enable the Company to make the right decisions in a timely manner.

Tenacity

There are many challenges in our field. Theratechnologies' employees do not shy away from a challenge and demonstrate resilience, drive and determination in finding innovative solutions and achieving the Company's goals.

Commitment

We are fully committed to market innovative therapies for orphan medical conditions. Our commitment also translates to our shareholders by continuously ensuring the growth of the Company.

Our History

Theratechnologies was founded in 1993.

Theratechnologies was founded in 1993. Scientists at Theratechnologies discovered EGRIFTA® (tesamorelin for injection) in 1995. For the next fifteen years, Theratechnologies pursued the development of this innovative treatment for lipodystrophy in people living with HIV. In 2010, Theratechnologies received a marketing authorization for EGRIFTA® from the Food and Drug Administration in the United States.

EGRIFTA® was first marketed by a third-party commercial partner in the United States. Then, in 2014, Theratechnologies made a strategic decision and reoriented its business model to become a commercial-stage biopharmaceutical company. This is when Theratechnologies regained commercial rights to EGRIFTA® in the United States.

This move gave Theratechnologies the means to look at other acquisitions which came shortly thereafter. In 2016, the Company concluded an agreement to acquire the commercial to Trogarzo® in the United States, Europe, Canada, Scandinavian countries, Russia, Israel and Switzerland. Trogarzo® was approved by the FDA in 2018 and was quickly adopted by hundreds of physicians to treat people living with a persistent HIV viral load.

Trogarzo® was approved in Europe in 2019. It is currently commercialized in Germany and other countries should soon follow. Several patients in Europe are already being treated through various early access programs funded by local governments.

An IV push and an intramuscular injection are currently being developed as part of the lifecycle management of Trogarzo®.

The Company is also pursuing the development of a novel and targeted approach for the treatment of solid tumors expressing the sortilin receptor. TH1902, the leading peptide-drug conjugate derived from Theratechnologies’ sortilin positive (SORT1+) Technology™, was granted a fast-track designation in early 2021 and the phase 1 clinical trial is now underway.

Theratechnologies also announced its intention to conduct a phase 3 clinical trial of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH). The initiation of the trial is expected in the third quarter of 2021.